Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | GABRP | O00591 | 4/20 | 0.41 |
| ▸ | GABRD | O14764 | 4/20 | 0.41 |
| ▸ | GABRA1 | P14867 | 4/20 | 0.41 |
| ▸ | GABRB1 | P18505 | 4/20 | 0.41 |
| ▸ | GABRG2 | P18507 | 4/20 | 0.41 |
| ▸ | GABRB3 | P28472 | 4/20 | 0.41 |
| ▸ | GABRA5 | P31644 | 4/20 | 0.41 |
| ▸ | GABRA3 | P34903 | 4/20 | 0.41 |
| ▸ | GABRA2 | P47869 | 4/20 | 0.41 |
| ▸ | GABRB2 | P47870 | 4/20 | 0.41 |
| ▸ | GABRA4 | P48169 | 4/20 | 0.41 |
| ▸ | GABRE | P78334 | 4/20 | 0.41 |
| ▸ | GABRA6 | Q16445 | 4/20 | 0.41 |
| ▸ | GABRG1 | Q8N1C3 | 4/20 | 0.41 |
| ▸ | GABRG3 | Q99928 | 4/20 | 0.41 |
| ▸ | GABRQ | Q9UN88 | 4/20 | 0.41 |
| ▸ | NAAA | Q02083 | 3/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31208321 | 0.87 | FBP1 (0.44) | MAPTLMNAGABRPGABRDGABRA1 | |
| SCHEMBL1748273 | 0.87 | FBP1 (0.44) | MAPTLMNAGABRPGABRDGABRA1 | |
| SCHEMBL1748081 | 0.81 | KDM4E (0.53) | MAPTLMNATP53GABRPGABRD | |
| SCHEMBL1748229 | 0.80 | PIK3CG (0.53) | MAPTLMNATP53FBP1 | |
| SCHEMBL29119767 | 0.80 | DAGLA (0.38) | MAPTLMNATP53DAGLACA12 | |
| SCHEMBL1748246 | 0.78 | APP (0.52) | MAPTLMNATP53GABRPGABRD | |
| SCHEMBL22382595 | 0.76 | FBP1 (0.42) | MAPTLMNATP53PTGS2FBP1 | |
| SCHEMBL305334 | 0.75 | LMNA (0.53) | MAPTLMNATP53PTGS2 | |
| SCHEMBL1748015 | 0.74 | SMN1; SMN2 (0.37) | MAPTTP53FBP1 | |
| SCHEMBL2490866 | 0.73 | SMN1; SMN2 (0.49) | MAPTGABRPGABRDGABRA1GABRB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240409533-A1 | HMOX1 INDUCERS | Astellas Engineered Small Molecules US, Incorporated | 2024-12-12 | — | — | US | disclosed |
| CN-113874074-B | HMOX1 inducers | 米托布里奇公司 | 2024-11-01 | — | — | CN | disclosed |
| US-12071433-B2 | HMOX1 inducers | Astellas Engineered Small Molecules US, Incorporated (US) | 2024-08-27 | — | — | US | disclosed |
| US-20240051952-A1 | HMOX1 INDUCERS | Astellas Engineered Small Molecules US, Incorporated | 2024-02-15 | — | — | US | disclosed |
| CN-115925651-B | Photochemical synthesis method of benzoxazole-2-alkyl alcohol | 合肥工业大学 | 2023-12-05 | — | — | CN | disclosed |
| US-20220177460-A1 | HMOX1 INDUCERS | Astellas Engineered Small Molecules US, Incorporated | 2022-06-09 | — | — | US | disclosed |
| US-20220177460-A1 | HMOX1 INDUCERS | Astellas Engineered Small Molecules US, Incorporated | 2022-06-09 | — | — | US | disclosed |
| EP-3952990-A1 | HMOX1 INDUCERS | Mitobridge, Inc. (US) | 2022-02-16 | — | — | EP | disclosed |
| CN-113874074-A | HMOX1 inducers | 米托布里奇公司 | 2021-12-31 | — | — | CN | disclosed |
| WO-2020210339-A1 | HMOX1 INDUCERS | MITOBRIDGE, INC. (US) | 2020-10-15 | — | — | WO | disclosed |
| US-7968576-B2 | Preparation and use of aryl alkyl acid derivatives for the treatment of obesity | SMITH ROGER A | 2011-06-28 | — | — | US | disclosed |
| US-20090270468-A1 | Preparation and use of aryl alkyl acid derivatives for the treatment of obesity | SMITH ROGER | 2009-10-29 | — | — | US | disclosed |
| US-20090253762-A1 | PREPARATION AND USE OF ARYL ALKYL ACID DERIVATIVES FOR THE TREATMENT OF OBESITY | SMITH ROGER | 2009-10-08 | — | — | US | disclosed |
| US-20090197795-A1 | PREPARATION AND USE OF ARYL ALKYL ACID DERIVATIVES FOR THE TREATMENT OF OBESITY | BAYER HEALTHCARE LLC (US) | 2009-08-06 | — | — | US | disclosed |
| US-7423156-B2 | Preparation and use of aryl alkyl acid derivatives for the treatment of obesity | BAYER PHARMACEUTICALS CORPORATION (US) | 2008-09-09 | — | — | US | disclosed |
| US-20060194859-A1 | Preparation and use of aryl alkyl acid derivatives for the treatment of obesity | BAYER PHARMACEUTICALS CORPORATION (US) | 2006-08-31 | — | — | US | disclosed |
| US-7091228-B2 | Preparation and use of aryl alkyl acid derivatives for the treatment of obesity | BAYER PHARMACEUTICALS CORPORATION (US) | 2006-08-15 | — | — | US | disclosed |
| EP-1633722-A2 | PREPARATION AND USE OF ARYL ALKYL ACID DERIVATIVES FOR THE TREATMENT OF OBESITY | Bayer Pharmaceuticals Corporation (US) | 2006-03-15 | — | — | EP | disclosed |
| WO-2004100881-A2 | PREPARATION AND USE OF ARYL ALKYL ACID DERIVATIVES FOR THE TREATMENT OF OBESITY | BAYER PHARMACEUTICALS CORPORATION (US) | 2004-11-25 | — | — | WO | disclosed |
| US-20040224997-A1 | Preparation and use of aryl alkyl acid derivatives for the treatment of obesity | BAYER PHARMACEUTICALS CORPORATION | 2004-11-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040224997-A1 | Preparation and use of aryl alkyl acid derivatives for the treatment of obesity | FABP4, GPR119, LIPC | MAPT 4379/4885LMNA 844/4885TP53 4669/4885 |
| US-20060194859-A1 | Preparation and use of aryl alkyl acid derivatives for the treatment of obesity | FABP4, GPR119, LIPC | MAPT 4379/4885LMNA 844/4885TP53 4669/4885 |
| US-20090270468-A1 | Preparation and use of aryl alkyl acid derivatives for the treatment of obesity | FABP4, GPR119, LIPC | MAPT 4379/4885LMNA 844/4885TP53 4669/4885 |
| US-20240409533-A1 | HMOX1 INDUCERS | HMOX1, HMOX2, HMBS | MAPT 3846/4885LMNA 3346/4885TP53 2737/4885 |
| US-12071433-B2 | HMOX1 inducers | HMOX1, HMOX2, HMBS | MAPT 3756/4885LMNA 3437/4885TP53 3076/4885 |
| US-20240051952-A1 | HMOX1 INDUCERS | HMOX1, HMOX2, QSOX1 | MAPT 3238/4885LMNA 1942/4885TP53 3570/4885 |
| US-20090197795-A1 | PREPARATION AND USE OF ARYL ALKYL ACID DERIVATIVES FOR THE TREATMENT OF OBESITY | FABP4, GPR119, LIPC | MAPT 4379/4885LMNA 844/4885TP53 4669/4885 |
| US-20220177460-A1 | HMOX1 INDUCERS | HMOX1, HMOX2, HMBS | MAPT 3756/4885LMNA 3437/4885TP53 3076/4885 |
| US-20090253762-A1 | PREPARATION AND USE OF ARYL ALKYL ACID DERIVATIVES FOR THE TREATMENT OF OBESITY | FABP4, GPR119, LIPC | MAPT 4379/4885LMNA 844/4885TP53 4669/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.